EXTH-72. CONTINUOUS INFUSION STUDIES REVEAL THE POTENCY OF ELACRIDAR TO ACT AS A PHARMACO-ENHANCER FOR TREATMENT OF INTRACRANIAL DISEASES BY INHIBITING ABCB1 AND ABCG2 AT THE BLOOD-BRAIN BARRIER

The blood-brain barrier (BBB) is a formidable hurdle to successful pharmacotherapy of intracranial diseases. ABCB1 and ABCG2 are efflux transporters that play an important role in the BBB, keeping substances out of the brain. Elacridar and tariquidar are third-generation ABCB1-inhibitors developed f...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: van Tellingen, Olaf, de Gooijer, Mark C, Zuidema, Stefanie, Meurs, Amber, Çitirikkaya, Ceren H, Venekamp, Nikkie, Beijnen, Jos H
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Preclinical Experimental Therapeutics
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651375/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.426
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki